Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Top 100 Creative Companies

- PMLiVE

Ashfield appoints new UK head of patient solutions

Stephanie Hill strengthens the commercial team at leading healthcare network

- PMLiVE

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...

OPEN Health

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

- PMLiVE

Myovant preps US filing for relugolix in prostate cancer

Takeda-partnered drug had 97% response rate in advanced prostate cancer

- PMLiVE

The Medicines Company surges on rumours of Novartis takeover

Buyers interested in company as it prepares to file CV drug inclisiran

The Unhappiness Project

How come I can’t find anyone who is ‘happy’ with healthcare?

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

- PMLiVE

Alkermes boosts CNS presence with $950m Rodin acquisition

Follows company making job cuts in September as part of cost-saving efforts

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links